email@mymsaa.org
Multiple Sclerosis Association of America Logo
Link to FaceBook Link to Twitter Link to YouTube Link to Pinterest
Improving Lives Today!
donate
About MS
MS Overview
Newly Diagnosed
Symptoms
Treatments
Online Webinars & Videos
MSAA Publications
Prescription Assistance Programs
Toll-Free Helpline
Clinical Trial Information
Información en Español
FAQs



Home > About MS > Clinical Trials Resource Center

FDA Approved Drugs » Therapeutic Areas

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

FDA Approved Drugs by Therapeutic Area

Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Click on an area below to view the complete list of drugs in that category or review descriptions for our therapeutic area list to assist you in your search.

Find out more about the types of drugs included in this listing.

FDA Approved Drugs for Endocrinology

Drugs Approved in 2014

Aveed (testosterone undecanoate) injection; Endo Pharmaceuticals; For the treatment of hypogonadism, Approved March 2014

Farxiga (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014

Tanzeum (albiglutide); GlaxoSmithKline; For the treatment of type II diabetes mellitus, Approved April 2014

Drugs Approved in 2013

Brisdelle (low-dose paroxetine mesylate); Noven Pharmaceuticals; For the treatment of vasomotor symptoms of menopause, Approved July 2013

Duavee (conjugated estrogens/bazedoxifene); Pfizer; For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis, Approved October 2013

Invokana (canagliflozin); Janssen Pharmaceuticals; For the treatment of type II diabetes mellitus, Approved April 2013

Nesina (alogliptin); Takeda; For the treatment of type II diabetes mellitus, Approved January 2013

Osphena (ospemifene); Shionogi; For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause, Approved March 2013

Drugs Approved in 2012

Belviq (lorcaserin hydrochloride); Arena Pharmaceuticals; For the chronic management of weight loss, Approved June 2012

Bio-T-Gel (testosterone gel); Teva Pharmaceutical; For the treatment of hypogonadism, Approved February 2012

Cometriq (cabozantinib); Exelixis; For the treatment of metastatic medullary thyroid cancer, Approved November 2012

Elelyso (taliglucerase alfa); Pfizer; For the treatment of Gaucher disease, Approved May 2012

Jentadueto (linagliptin plus metformin hydrochloride); Eli Lilly; For the treatment of type II diabetes, Approved February 2012

Korlym (mifepristone); Corcept Therapeutics; For the control of hyperglycemia in adults with endogenous Cushing’s syndrome, Approved February 2012

Lucentis (ranibizumab injection); Genentech; For the treatment of diabetic macular edema, Approved August 2012

Qsymia (phentermine + topiramate extended-release); Vivus; For the treatment of chronic weight management, Approved July 2012

Signifor (pasireotide diaspartate); Novartis; For the treatment of Cushing's disease, Approved December of 2012

Ultresa (pancrelipase) delayed-release capsules; Aptalis Pharma; For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions, Approved March 2012

Viokace (pancrelipase) tablets; Aptalis Pharma; For the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy, Approved March 2012

Drugs Approved in 2011

Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011

Juvisync (sitagliptin and simvastatin); Merck; For the treatment of type II diabetes, Approved October 2011

Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011

Tradjenta (linagliptin); Boehringer Ingelheim; For the treatment of type II diabetes, Approved May 2011

Drugs Approved in 2010

Fortesta (testosterone gel); Endo Pharmaceuticals; For the treatment of hypogonadism, Approved December 2010

Prolia (denosumab); Amgen; For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved June 2010

Victoza (liraglutide); Novo Nordisk; For the treatment of type 2 diabetes mellitus, Approved January 2010

Drugs Approved in 2009

Cycloset, bromocriptine mesylate; VeroScience; For the treatment of type 2 diabetes mellitus, Approved May 2009

Onglyza (saxagliptin); Bristol-Myers Squibb; For the treatment of type 2 diabetes mellitus, Approved July 2009

Drugs Approved in 2008

Accretropin (somatropin rDNA Original); Cangene; For the treatment of growth failure in pediatrics, Approved January 2008

Welchol (colesevelam hydrochloride); Daiichi Sankyo; For the improvement of glycemic control in adults with type 2 diabetes mellitus, Approved January 2008

Drugs Approved in 2007

Evamist (estradiol); Vivus; For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007

Fenofibrate; LifeCycle Pharma; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007

Somatuline Depot (lanreotide acetate); Beaufour Ipsen; For the treatment of acromegaly, Approved August 2007

Supprelin LA (histrelin acetate); Indevus Pharmaceuticals; For the treatment of central precocious puberty, Approved May 2007

Drugs Approved in 2006

Elestrin (estradiol gel); BioSante; For the treatment of vasomotor symptoms associated with menopause, Approved December 2006

Januvia (sitagliptin phosphate); Merck; For the treatment of type II diabetes, Approved October 2006

Drugs Approved in 2005

ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride); Takeda; For the treatment of type 2 diabetes, Approved August of 2005

Byetta (exenatide); Amylin/Eli Lilly; For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005

Increlex (mecasermin); Tercica; For the treatment of growth failure due to Primary IGFD, Approved August 2005

Symlin (pramlintide); Amylin Pharmaceuticals; For the treatment of type I and type II diabetes, Approved March 2005

Drugs Approved in 2003

Aldurazyme (laronidase); Genzyme; For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003

Fabrazyme (agalsidase beta); Genzyme; For the treatment of Fabry disease in adult patients, Approved April 2003

Somavert (pegvisomant); Pharmacia & Upjohn; Injectable formulation for the treatment of acromegaly, Approved March 2003

Drugs Approved in 2002

Avandamet (rosiglitazone maleate and metformin HCl); GlaxoSmithKline; For improvement of glycemic control in type 2 diabetes patients, Approved October 2002

Benicar; Daiichi Sankyo; Oral tablet for the treatment of hypertension, Approved April 2002

Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals; Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002

Forteo (teriparatide); Eli Lilly; For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002

Levo-T (levothyroxine sodium); Mova Pharmaceutical; Indicated for the treatment of hypothyroidism and the suppression of thyroid stimulating hormone, Approved March 2002

Metaglip (glipizide/metformin HCl); Bristol-Myers Squibb; Oral tablets for the treatment of type 2 diabetes., Approved October 2002

Novothyrox (levothyroxine sodium); Genpharm; For the treatment of hypothyroidism and suppression of thyroid-stimulating hormone, Approved May 2002

Synthroid (levothyroxine sodium); Abbott Laboratories; For replacement or supplemental therapy for hypothyroidism and pituitary thyroid stimulating hormone suppression, Approved July 2002

Testim; Auxilium Pharmaceuticals; External cream for the treatment of male hormone deficiency., Approved October 2002

Drugs Approved in 2001

Campath; Berlex Laboratories; Injectable treatment of B-cell chronic lymphocytic leukemia, Approved May 2001

Diovan (valsartan); Novartis; Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)

Femara (letrozole); Novartis; First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001

Genotropin (somatropin) injection; Pharmacia & Upjohn; For the treatment of growth failure in children who were born small for gestational age (SGA), Approved July 2001

Gleevec (imatinib mesylate); Novartis; Oral therapy for the treatment of chronic myeloid leukemia, Approved May 2001

Levoxyl; Jones Pharma; Oral therapy for the treatment of hypothyroidism and suppression of thyroid-stimulating hormone (TSH), Approved May 2001

Natrecor (nesiritide); Scios; For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001

Novolog Mix 70/30; Novo Nordisk; Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes, Approved November 2001

Prozac Weekly (fluoxetine HCl); Eli Lilly; For the treatment of depression, Approved February 2001

Remeron SolTab (mirtazapine); Organon; Orally disintegrating tablet for the treatment of depression, Approved January 2001

Remicade (infliximab); Centocor Ortho Biotech; For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001

Trelstar LA (triptorelin pamoate); Debiopharm; Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001

Yasmin (drospirenone/ethinyl estradiol); Berlex Laboratories; Oral contraceptive, Approved May 2001

Zometa (zoledronic acid); Novartis; For the treatment of hypercalcemia of malignancy, Approved August 2001

Drugs Approved in 2000

Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk; Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000

AndroGel testosterone gel; Unimed Pharmaceuticals; For testosterone replacement therapy in males with testosterone deficiency, Approved February 2000

Atacand (candesartan cilexetil); AstraZeneca; For the treatment of hypertension, Approved September 2000

Cetrotide; Asta Medica; For the prevention of premature ovulation in women undergoing controlled ovarian stimulation, Approved August 2000

Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories; For the reduction of high blood pressure, Approved January 2000

Hectorol (Doxercalciferol) Injection; Bone Care International; To reduce iPTH levels in management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis, Approved April 2000

Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis; For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia, Approved April 2000

Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis; For the treatment of type I and type II diabetes mellitus in adults and pediatrics, Approved April 2000

Lescol XL (fluvastatin sodium) tablet, extended release; Novartis; For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000

Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim; For the treatment of hypertension, Approved November 2000

Mirena (levonorgestrel-releasing intrauterine system); Berlex Laboratories; Hormone-releasing system for intrauterine contraception, Approved December 2000

NovoLog (insulin aspart); Novo Nordisk; An insulin analogue for the treatment of diabetes mellitus., Approved June 2000

Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories; For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000

Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates; For the palliative treatment of advanced prostate cancer, Approved June 2000

Viadur (leuprolide acetate implant); Alza; For pain relief in men with advanced prostate cancer, Approved March 2000

Vivelle (estradiol transdermal system); Novartis; For the prevention of postmenopausal osteoporosis, Approved August 2000

Drugs Approved in 1999

ACTOS; Takeda; Treatment for type II diabetes, Approved July 1999

Aggrenox; Boehringer Ingelheim; Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999

Aromasin Tablets; Pharmacia & Upjohn; Exemestane Tablets, 25 mg, October 21, 1999

Avandia (rosiglitazone maleate); SmithKline Beecham; Treatment for type II diabetes mellitus, Approved June 1999

Cernevit; Baxter Healthcare; For the treatment of vitamin deficiency, Approved April 1999.

Climara; Berlex Laboratories; For the prevention of postmenopausal osteoporosis (loss of bone mass), Approved June 1999

Doxil (doxorubicin HCl liposome injection); Alza; Treatment for ovarian cancer that is refractory to other first-line therapies, Approved June 1999

Ellence; Pharmacia & Upjohn; epirubicin hydrochloride, Approved September 1999

Ethyol (amifostine); US Bioscience, Alza; Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999

Evista (raloxifene hydrochloride); Eli Lilly; Osteoporosis treatment, Approved September 1999

Femhrt Tablets; Parke-Davis; Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999

Ortho-Prefest; Ortho-McNeil Pharmaceutical, RW Johnson; 17 beta estradiol/17 beta estradiol norgestimate tablets, October 22, 1999

Xenical/Orlistat Capsules; Roche; Treatment for obesity management, Approved April 1999

Drugs Approved in 1998

Actonel; Procter & Gamble, Hoechst Marion Roussel; Treatment for Paget's Disease, Approved April 1998

Arava; Hoechst Marion Roussel; Treatment for Rheumatoid Arthritis, Approved September 1998

Celexa; Forest Laboratories; Treatment for depression, Approved July 1998

CellCept; Roche; Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998

Clomipramine hydrochloride; Mylan Laboratories; Generic equivalent of Anafranil, Approved April 1998

Diovan HCT (valsartan); Novartis; Treatment for hypertension, Approved March 1998

Esclim; Fournier Research; Treatment for symptoms associated to Menopause, Approved August 1998

Estratab (.3 mg ); Solvay Pharmaceuticals; Treatment for the prevention of osteoporosis, Approved March 1998

Glucagon; Eli Lilly; Treatment for severe hypoglycemia associated with diabetes., Approved October 1998

Glucagon; Eli Lilly; Treatment for severe Hypoglycemia, Approved September 1998

Glyburide Tablets; Mylan Laboratories; Treatment for Diabetes Mellitus (Type II), Approved July 1998.

Herceptin; Genentech; Treatment for metastatic breast cancer, Approved October 1998

Inform HER-2/neu breast cancer test; Oncor; Treatment for breast cancer prediction, Approved January 1998

Marplan Tablets; Roche; Treatment of Depression, Approved August 1998

Mircette; Organon; Oral contraceptive, Approved April 1998

Prempro; Wyeth; Treatment for hormone replacement therapy, Approved January 1998

Prometrium; Schering-Plough; Treatment for Endometrial Hyperplasia, Approved December 1998

Proscar; Merck; Treatment for complication relating to benign prostatic hyperplasia (BPH), Approved April 1998

Simulect; Novartis; Treatment for acute organ transplant rejection, Approved May 1998

Xeloda; Roche; Treatment for advanced breast cancer tumors, Approved April 1998

Zemplar; Abbott Laboratories; Treatment of secondary hyperparathyroidism associated with chronic renal failure, Approved April 1998

Drugs Approved in 1997

Baycol (cerivastatin sodium); Bayer; Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01

Captopril and hydrochlorotiazide; Mylan Laboratories; Treatment for hypertension, Approved May 1997

Corlopam; Neurex; Treatment for severe high blood pressure, Approved September 1997

Crinone 8% (progesterone gel); Wyeth; Treatment for infertile women with pregestone deficiency, Approved May 1997

Diovan (valsartan); Ciba Pharmaceuticals; Treatment for hypertension, Approved January 1997

Dostinex Tablets (cabergoline tablets); Pharmacia & Upjohn; Treatment of hyperprolactinemic disorders, Approved January 1997

DynaCirc CR; Novartis; Treatment for hypertension, Approved February 1997

Effexor XR (venlafaxin HCI); Wyeth; Treatment of depression, Approved October 1997

Estradiol tablets; Barr Laboratories; Generic equivalent of Estrace, Approved October 1997

Estradiol tablets; Duramed Pharmaceuticals; Generic equivalent of Estrace tablets, Approved December 1997

Estrostep (norethindrone acetate and ethinyl estradiol); Warner-Lambert; Treatment for oral contraception, Approved March 1997

Etodolac; Royce Laboratories; Generic equivalent of Lodine, Approved April 1997

Evista (raloxifene hydrochloride); Eli Lilly; Treatment for the prevention of osteoporosis, Approved December 1997

Femara (letrozole); Novartis; Treatment for breast cancer, Approved July 1997

Follistim (TM) (follitropin beta for injection); Organon; Treatment for infertility, Approved September 1997

Genotropin (somatropin) lyophilized powder; Pharmacia & Upjohn; Treatment for growth hormone deficiency in adults, Approved November 1997

Geref (sermorelin acetate for injection); Serono Laboratories; Treatment for pedicatric growth disorder, Approved October 1997

Gliadel Wafer (polifeprosan 20 with carmustine implant); Rhone-Poulenc Rorer, Guilford Pharmaceuticals; Treatment for brain cancer, Approved February 1997

Glipizide Tablets; Duramed Pharmaceuticals; Treatment for diabetes, Approved September 1997

Glyburide Tablets; Roche; Treatment for blood-glucose lowering, Approved December 1997

Glyburide Tablets; Mova Pharmaceutical; Generic version of Glynase PresTab, Approved December 1997

Gonal-F (follitropin alfa for injection); Serono Laboratories; Treatment for infertility, Approved September 1997

Lescol (fluvastatin sodium); Novartis; Treatment for coronary atherosclerosis, Approved September 1997

Lexxel (enalapril maleate-felodipine ER); Astra Merck; Treatment for hypertension, Approved January 1997

MERIDIA; Knoll Pharmaceutical; Treatment for obesity, Approved November 1997

Microzide (hydrochlorothiazide); Watson Pharmaceuticals; Treatment for mild-to moderate hypertension, Approved January 1997

Norditropin (somatropin (rDNA origin) for injection); Novo Nordisk; Treatment of children who have growth failure, Approved February 1997

Nutropin (somatropin-rDNA origin); Genentech; Treatment for growth hormone deficiency, Approved December 1997

Pindolol; Teva Pharmaceutical; Generic equivalent of Visken, Approved April 1997

Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb; Treatment for cardiac atherosclerotic events, Approved November 1997

Posicor; Roche; Treatment for hypertension and chronic stable angina pectoris, Approved June 1997

Prandin; Novo Nordisk; Treatment for Type II diabetes, Approved December 1997

Prograf; Fujisawa Healthcare; Treatment for the prevention of kidney transplant rejection, Approved April 1997

REGRANEX (becaplermin) Gel; RW Johnson; Treatment for diabetic foot ulcers, Approved December 1997

REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals; Generic equivalent of Pergonal, Approved February 1997

Skelid (tiludronate disodium); Sanofi-aventis; Treatment for Paget’s disease of bone, Approved March 1997

Testoderm TTS CIII; Alza; Treatment for testosterone deficiency, Approved December 1997

Teveten (eprosartan mesylate); SmithKline Beecham; Treatment for hypertension, Approved December 1997

Trazadone 150mg; Teva Pharmaceutical; Generic equivalent of Desyrel 7, Approved May 1997

Trivora-21 and Trivora-28; Watson Pharmaceuticals; Generic equivalents of levonorgestrel and ethinyl estradiol, Approved December 1997

Verapamil; IVAX; Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997

Zenapax; Roche; Treatment to prevent rejection of kidney transplants, Approved December 1997

Zerit (stavudine); Bristol-Myers Squibb; Treatment for infants and children infected with HIV, Approved January 1997

Drugs Approved in 1996

Aredia (pamidronate disodium for injection); Chiron; Treatment for osteolytic bone metastases of breast cancer, Approved August 1996

Arimidex (anastrozole); AstraZeneca; Treatment for advanced breast cancer in postmenopausal women, Approved January 1996

Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996

Campostar; Pharmacia & Upjohn; Treatment for metastatic colorectal cancer, Approved June 1996

CEA-Scan; Immunomedics; Diagnostic imaging product for colorectal cancer, Approved April 1996

Confide; Johnson & Johnson; HIV testing and counseling service, Approved May 1996

Covera-HS (verapamil); GD Searle, Alza; Treatment for hypertension and angina, Approved January 1996

Desmopressin Acetate (DDAVP); Rhone Poulenc Rorer; Treatment for central diabetes insipidus, Approved February 1996

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection); Orphan Medical; Treatment of meningeal leukemia or lymphocytic lymphoma, Approved October 1996

Estrostep (norethindrone acetate and ethinyl estradiol); Parke-Davis; Treatment for birth control, Approved October 1996

Eulexin (flutamide); Schering-Plough; Treatment for prostate cancer, Approved June 1996

FemPatch; Parke-Davis; Treatment for menopausal symptoms, Approved December 1996

Fertinex (urofollitropin for injection, purified); Serono Laboratories; Treatment for patients undergoing infertility treatments, Approved September 1996

Gemzar (gemcitabine HCL); Eli Lilly; Treatment for pancreatic cancer, Approved May 1996

Glyset (miglitol); Bayer; Treatment for Type II (non-insulin-dependent) diabetes mellitus, Approved December 1996

Humalog (insulin lispro); Eli Lilly; Treatment for type I and type II diabetes, Approved June 1996

Humatrope (somatropin [rDNA origin] for injection); Eli Lilly; Treatment for Somatropin Deficiency Syndrome, Approved August 1996

Hycamtin (topotecan hydrochloride); SmithKline Beecham; Treatment for metastatic ovarian cancer, Approved May 1996

Lithobid (Lithium Carbonate); Solvay Pharmaceuticals; Treatment for manic depression, Approved January 1996

Lodine (etodolac); Wyeth; Treatment for rheumatoid arthritis, Approved July 1996

Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories; Treatment for advanced prostate cancer, Approved January 1996

Mavik (trandolapril); Knoll Pharmaceutical; Treatment for hypertension, Approved May 1996

Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth; Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996

Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals; Treatment for vitamin B-12 deficiency, Approved November 1996

Nutropin (somatropin-rDNA origin); Genentech; Treatment that consists of recombinant growth hormone product, Approved January 1996

OxyContin (oxycodone HCl controlled-release); Purdue Pharma; Treatment for pain associated with musculoskeletal conditions, Approved May 1996

Pravachol (pravastatin sodium); Bristol-Myers Squibb; Treatment for cholesterol-lowering, Approved July 1996

Redux (dexfenfluramine hydrochloride); Wyeth; Treatment for obesity, Approved May 1996

Remeron (Mirtazapine); Organon; Treatment for depression, Approved June 1996

Saizen; Ares-Serono; Treatment for growth hormone deficiency and Turner Syndrome, Approved May 1996

Taxotere (Docetaxel); Rhone Poulenc Rorer; Treatment for locally advanced or metastatic breast cancer, Approved May 1996

Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel; Treatment for hypertension, Approved October 1996

Tiazac (diltiazem hydrochloride); Forest Laboratories; Treatment for hypertension, Approved February 1996

Vivelle (estradiol transdermal system); Ciba Pharmaceuticals; Treatment for moderate and severe vasomotor menopausal symptoms, Approved March 1996

Zoladex (10.8 mg goserelin acetate implant); AstraZeneca; Treatment for advanced prostate cancer, Approved January 1996

Drugs Approved in 1995

Amaryl (Glimepiride); Hoechst Marion Roussel; Treatment for type II diabetes, Approved December 1995

Androderm (Testosterone Transdermal System); TheraTech; Treatment for primary and secondary hypogonadism, Approved on September 29, 1995

Epivir (lamivudine); GlaxoSmithKline; Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995

Ethyol (amifostine); Alza; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995

Fosamax (alendronate sodium); Merck; Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995

Invirase (saquinavir); Roche; Treatment for HIV/AIDS, Approved on December 7, 1995

Leukine (sargramostim); Immunex; Treatment for mobilizing peripheral blood progenitor cells for use after transplantation., Approved on November 24, 1995

Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals; Treatment for post-menopausal osteoporosis, Approved on August 17, 1995

Precose (acarbose); Bayer; Treatment for non-insulin-dependent diabetes mellitus, Approved September 6, 1995

Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth; Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995

Prinivil or Zestril (Lisinopril); Merck, Zeneca; Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995

Western blot confirmatory device; Epitope; Confirmatory test for HIV, Approved in December 1995